Coloplast AS Class B

COLO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
<rpLOCK|C&QZ@LOCK|&!F@Fn!

Coloplast Earnings: Typical Top-Line Growth Is Coupled With Margin Pressure; Maintaining Fair Value

Consistent with its long-term revenue growth profile, Coloplast delivered fiscal first-quarter top-line growth of 8%, though operating margin was held down at 27%.

Sponsor Center